 <h1>Gimoti Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>metoclopramide</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about metoclopramide. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Gimoti.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to metoclopramide: oral solution, oral tablet, oral tablet disintegrating</i></p><p>Other dosage forms:</p><ul><li>solution</li></ul><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with duration of treatment and total cumulative dose. Discontinue metoclopramide in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide is stopped. Avoid treatment with Reglan for longer than 12 weeks because of the increased risk of developing TD with longer-term use.</p><p class="blackboxWarning-title">Oral route (Tablet, Disintegrating; Solution)</p><p>Metoclopramide treatment can cause tardive dyskinesia, a serious movement disorder that is often irreversible. Risk is increased with duration of treatment and total cumulative dose. Discontinue metoclopramide therapy in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia, although symptoms may lessen or resolve after metoclopramide discontinuation. Prolonged treatment with metoclopramide (greater than 12 weeks) should be avoided in all but rare cases where therapeutic benefit outweighs the risks.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, metoclopramide (the active ingredient contained in Gimoti) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking metoclopramide:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Chills</li>
<li>clay colored stools</li>
<li>dark urine</li>
<li>difficulty with breathing</li>
<li>difficulty with speaking or swallowing</li>
<li>dizziness or fainting</li>
<li>fast or irregular heartbeat</li>
<li>fever</li>
<li>general feeling of tiredness or weakness</li>
<li>headache (severe or continuing)</li>
<li>inability to move the eyes</li>
<li>increase in blood pressure</li>
<li>increased sweating</li>
<li>itching, skin rash</li>
<li>lip smacking or puckering</li>
<li>loss of appetite</li>
<li>loss of balance control</li>
<li>loss of bladder control</li>
<li>mask-like face</li>
<li>muscle spasms of the face, neck, and back</li>
<li>nausea</li>
<li>puffing of the cheeks</li>
<li>rapid or worm-like movements of the tongue</li>
<li>seizures</li>
<li>shuffling walk</li>
<li>sore throat</li>
<li>stiffness of the arms or legs</li>
<li>stomach pain or tenderness</li>
<li>swelling of the feet or lower legs</li>
<li>tic-like or twitching movements</li>
<li>trembling and shaking of the hands and fingers</li>
<li>twisting movements of the body</li>
<li>uncontrolled chewing movements</li>
<li>uncontrolled movements of the arms and legs</li>
<li>unusually pale skin</li>
<li>vomiting</li>
<li>weakness of the arms and legs</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking metoclopramide:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Confusion</li>
<li>drowsiness (severe)</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of metoclopramide may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
<li>drowsiness</li>
<li>loss of strength or energy</li>
<li>muscle pain or weakness</li>
<li>restlessness</li>
<li>unusual weak feeling</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Breast tenderness and swelling</li>
<li>changes in menstruation</li>
<li>constipation</li>
<li>decreased interest in sexual intercourse</li>
<li>inability to have or keep an erection</li>
<li>increased flow of breast milk</li>
<li>increased need to urinate</li>
<li>loss in sexual ability, desire, drive, or performance</li>
<li>mental depression</li>
<li>passing urine more often</li>
<li>skin rash</li>
<li>trouble sleeping</li>
<li>unusual dryness of the mouth</li>
<li>unusual irritability</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to metoclopramide: compounding powder, injectable solution, oral concentrate, oral syrup, oral tablet, oral tablet disintegrating</i></p><h3>General</h3><p>The incidence of side effects correlates with dose and duration of metoclopramide (the active ingredient contained in Gimoti) therapy.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Drowsiness, decreased level of consciousness, confusion, and hallucinations have higher incidences with higher doses.</p>
<p></p>
<p>Convulsive seizures have been reported, especially in patients with epilepsy; however, there is no obvious association with use of this drug.</p>
<p></p>
<p>Dystonic reactions typically presented as upper airway obstruction with stridor and dyspnea.</p>
<p></p>
<p>Parkinsonian symptoms may be related to usual/excessive doses and/or decreased renal function and includes tremor, rigidity, bradykinesia, and akinesia.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Drowsiness (up to 70%), acute dystonic reaction (up to 25%)</p>
<p><b>Common</b> (1% to 10%): Akathisia, dizziness, extrapyramidal disorders, headache, parkinsonism, somnolence</p>
<p><b>Uncommon</b> (0.1% to 1%): Depressed level of consciousness, dyskinesia, dystonia</p>
<p><b>Rare</b> (0.01% to 0.1%): Bradykinesia, convulsion, dystonic reaction, tremor</p>
<p><b>Very rare</b> (less than 0.01%): Neuroleptic malignant syndrome</p>
<p><b>Frequency not reported</b>: Acute dyskinesia, acute dystonia/acute dystonic reaction, altered consciousness, autonomic instability, bulbar type of speech, choreoathetotic movements, cogwheel rigidity, convulsive seizures, extrapyramidal symptoms, facial grimacing, facial muscle spasm, fatal dystonic reaction, foot tapping, inability to sit still, involuntary movements of the extremities/face/jaw/mouth/tongue/trunk, mask-like facies, motor restlessness, opisthotonos, pacing, parkinsonian syndrome, rhythmic tongue protrusion, serotonin syndrome, syncope, tardive dyskinesia, tetanus-like reaction, unnatural position of head and shoulders<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea, nausea, vomiting</p>
<p><b>Uncommon</b> (0.1% to 1%): Bowel disturbances</p>
<p><b>Rare</b> (0.01% to 0.1%): Supraglottic dystonia</p>
<p><b>Frequency not reported</b>: Glossal edema<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Asthenia, fatigue, lassitude</p>
<p><b>Frequency not reported</b>: Effects on the ability to drive/operate machinery, hyperpyrexia, hyperthemia, jitteriness<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, restlessness</p>
<p><b>Uncommon</b> (0.1% to 1%): Hallucination, insomnia</p>
<p><b>Rare</b> (0.01% to 0.1%): Acute depression, confusional state</p>
<p><b>Frequency not reported</b>: Agitation, anxiety, confusion, delirium, mania, mental depression with suicidal ideation, nervousness, obsessive rumination, severe dysphoria, suicidal ideation, suicide<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypotension</p>
<p><b>Uncommon</b> (0.1% to 1%): Bradycardia</p>
<p><b>Very rare</b> (less than 0.01%): Cardiac conduction abnormalities, heart block</p>
<p><b>Frequency not reported</b>: Acute congestive heart failure, acute hypertension, atrial fibrillation, atrioventricular (AV) block, cardiac arrest, edema, electrocardiogram QT prolonged, fatal cardiorespiratory arrest, hypertension, palpitation, possible AV block, shock, sinus arrest, supraventricular tachycardia, tachycardia, Torsade de Pointes, transient facial/upper body flushing, transient increase in blood pressure, ventricular fibrillation, ventricular tachycardia<sup>[Ref]</sup></p><p>Hypotension, bradycardia, shock, and other abnormalities or cardiac conduction occurred most frequently with IV formulations.</p>
<p></p>
<p>Cardiac arrest occurred shortly after IV administration, and may have been subsequent to bradycardia.</p>
<p></p>
<p>Sinus arrest and transient facial/upper body flushing occurred, particularly with IV administration.  Flushing typically occurred without alterations in vital signs following high dose IVs.</p>
<p></p>
<p>Edema/fluid retention may be secondary to a transient increase in aldosterone levels.</p>
<p></p>
<p>Acute hypertension has occurred in patients with pheochromocytoma.</p>
<p></p>
<p>Hypertension has occurred in patients with/without pheochromocytoma.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Impotence may be secondary to hyperprolactinemia.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Amenorrhea</p>
<p><b>Rare</b> (0.01% to 0.1%): Galactorrhea</p>
<p><b>Frequency not reported</b>: Breast enlargement, impotence, priapism, sexual dysfunction, urinary frequency, urinary incontinence<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Hyperprolactinemia</p>
<p><b>Frequency not reported</b>: Endocrine disorders, gynecomastia, transient aldosterone elevation<sup>[Ref]</sup></p><p>Amenorrhea, galactorrhea, and gynecomastia occurred secondary to hyperprolactinemia during prolonged treatment.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Anaphylactic reaction/shock typically occurred with the IV formulation.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p>
<p><b>Frequency not reported</b>: Anaphylactic reaction, anaphylactic shock, angioedema<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Bronchospasm, wheezing, and dyspnea typically occurred in patients with a history of asthma.</p>
<p></p>
<p>Respiratory failure occurred secondary to dystonic reactions.<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Dyspnea, laryngospasm, stridor, upper airway obstruction</p>
<p><b>Frequency not reported</b>: Acute asthmatic symptoms, bronchospasm, laryngeal edema, respiratory failure, wheezing<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Rare</b> (0.01% to 0.1%): Altered liver function tests, hepatotoxicity, jaundice<sup>[Ref]</sup></p><p>Hepatotoxicity occurred with concurrent use of other potentially hepatotoxic drugs and was characterized by findings such as jaundice and altered liver function tests.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Rare</b> (0.01% to 0.1%): Rigidity</p>
<p><b>Frequency not reported</b>: Fluid retention, generalized muscle tone increase, increased creatinine phosphokinase (CPK), muscle rigidity, muscle spasms, torticollis, trismus<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Agranulocytosis, blood disorders, leukopenia, methemoglobinemia, neutropenia, sulfhemoglobinemia<sup>[Ref]</sup></p><p>Leukopenia, neutropenia, and agranulocytosis typically did not have a clear-cut relationship with this drug.</p>
<p></p>
<p>Methemoglobinemia and sulfhemoglobinemia occurred with high doses of this drug.  Methemoglobinemia may be related to NADH cytochrome b5 reductase deficiency or overdose, particularly in neonates.  Sulfhemoglobinemia usually occurred in adults with concomitant use of high doses of sulfur-releasing products.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Angioneurotic edema, maculopapular rash, rash, urticaria<sup>[Ref]</sup></p><p>Rash and urticaria typically occurred in patients with a history of asthma.<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Extraocular muscle spasm, oculogyric crisis, visual disturbances<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Fluid retention, porphyria<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories, Philadelphia, PA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Gimoti (metoclopramide)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: GI stimulants</li>
<li>FDA Alerts (3)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Gimoti &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Reglan, Metozolv ODT</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Gastroparesis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to metoclopramide: compounding powder, injectable solution, oral concentrate, oral syrup, oral tablet, oral tablet disintegrating</i></p><h3>General</h3><p>The incidence of side effects correlates with dose and duration of metoclopramide (the active ingredient contained in Gimoti) therapy.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Drowsiness, decreased level of consciousness, confusion, and hallucinations have higher incidences with higher doses.</p><p></p><p>Convulsive seizures have been reported, especially in patients with epilepsy; however, there is no obvious association with use of this drug.</p><p></p><p>Dystonic reactions typically presented as upper airway obstruction with stridor and dyspnea.</p><p></p><p>Parkinsonian symptoms may be related to usual/excessive doses and/or decreased renal function and includes tremor, rigidity, bradykinesia, and akinesia.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Drowsiness (up to 70%), acute dystonic reaction (up to 25%)</p><p><b>Common</b> (1% to 10%): Akathisia, dizziness, extrapyramidal disorders, headache, parkinsonism, somnolence</p><p><b>Uncommon</b> (0.1% to 1%): Depressed level of consciousness, dyskinesia, dystonia</p><p><b>Rare</b> (0.01% to 0.1%): Bradykinesia, convulsion, dystonic reaction, tremor</p><p><b>Very rare</b> (less than 0.01%): Neuroleptic malignant syndrome</p><p><b>Frequency not reported</b>: Acute dyskinesia, acute dystonia/acute dystonic reaction, altered consciousness, autonomic instability, bulbar type of speech, choreoathetotic movements, cogwheel rigidity, convulsive seizures, extrapyramidal symptoms, facial grimacing, facial muscle spasm, fatal dystonic reaction, foot tapping, inability to sit still, involuntary movements of the extremities/face/jaw/mouth/tongue/trunk, mask-like facies, motor restlessness, opisthotonos, pacing, parkinsonian syndrome, rhythmic tongue protrusion, serotonin syndrome, syncope, tardive dyskinesia, tetanus-like reaction, unnatural position of head and shoulders<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea, nausea, vomiting</p><p><b>Uncommon</b> (0.1% to 1%): Bowel disturbances</p><p><b>Rare</b> (0.01% to 0.1%): Supraglottic dystonia</p><p><b>Frequency not reported</b>: Glossal edema<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Asthenia, fatigue, lassitude</p><p><b>Frequency not reported</b>: Effects on the ability to drive/operate machinery, hyperpyrexia, hyperthemia, jitteriness<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, restlessness</p><p><b>Uncommon</b> (0.1% to 1%): Hallucination, insomnia</p><p><b>Rare</b> (0.01% to 0.1%): Acute depression, confusional state</p><p><b>Frequency not reported</b>: Agitation, anxiety, confusion, delirium, mania, mental depression with suicidal ideation, nervousness, obsessive rumination, severe dysphoria, suicidal ideation, suicide<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypotension</p><p><b>Uncommon</b> (0.1% to 1%): Bradycardia</p><p><b>Very rare</b> (less than 0.01%): Cardiac conduction abnormalities, heart block</p><p><b>Frequency not reported</b>: Acute congestive heart failure, acute hypertension, atrial fibrillation, atrioventricular (AV) block, cardiac arrest, edema, electrocardiogram QT prolonged, fatal cardiorespiratory arrest, hypertension, palpitation, possible AV block, shock, sinus arrest, supraventricular tachycardia, tachycardia, Torsade de Pointes, transient facial/upper body flushing, transient increase in blood pressure, ventricular fibrillation, ventricular tachycardia<sup>[Ref]</sup></p><p>Hypotension, bradycardia, shock, and other abnormalities or cardiac conduction occurred most frequently with IV formulations.</p><p></p><p>Cardiac arrest occurred shortly after IV administration, and may have been subsequent to bradycardia.</p><p></p><p>Sinus arrest and transient facial/upper body flushing occurred, particularly with IV administration.  Flushing typically occurred without alterations in vital signs following high dose IVs.</p><p></p><p>Edema/fluid retention may be secondary to a transient increase in aldosterone levels.</p><p></p><p>Acute hypertension has occurred in patients with pheochromocytoma.</p><p></p><p>Hypertension has occurred in patients with/without pheochromocytoma.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Impotence may be secondary to hyperprolactinemia.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Amenorrhea</p><p><b>Rare</b> (0.01% to 0.1%): Galactorrhea</p><p><b>Frequency not reported</b>: Breast enlargement, impotence, priapism, sexual dysfunction, urinary frequency, urinary incontinence<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Hyperprolactinemia</p><p><b>Frequency not reported</b>: Endocrine disorders, gynecomastia, transient aldosterone elevation<sup>[Ref]</sup></p><p>Amenorrhea, galactorrhea, and gynecomastia occurred secondary to hyperprolactinemia during prolonged treatment.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Anaphylactic reaction/shock typically occurred with the IV formulation.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p><p><b>Frequency not reported</b>: Anaphylactic reaction, anaphylactic shock, angioedema<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Bronchospasm, wheezing, and dyspnea typically occurred in patients with a history of asthma.</p><p></p><p>Respiratory failure occurred secondary to dystonic reactions.<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Dyspnea, laryngospasm, stridor, upper airway obstruction</p><p><b>Frequency not reported</b>: Acute asthmatic symptoms, bronchospasm, laryngeal edema, respiratory failure, wheezing<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Rare</b> (0.01% to 0.1%): Altered liver function tests, hepatotoxicity, jaundice<sup>[Ref]</sup></p><p>Hepatotoxicity occurred with concurrent use of other potentially hepatotoxic drugs and was characterized by findings such as jaundice and altered liver function tests.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Rare</b> (0.01% to 0.1%): Rigidity</p><p><b>Frequency not reported</b>: Fluid retention, generalized muscle tone increase, increased creatinine phosphokinase (CPK), muscle rigidity, muscle spasms, torticollis, trismus<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Agranulocytosis, blood disorders, leukopenia, methemoglobinemia, neutropenia, sulfhemoglobinemia<sup>[Ref]</sup></p><p>Leukopenia, neutropenia, and agranulocytosis typically did not have a clear-cut relationship with this drug.</p><p></p><p>Methemoglobinemia and sulfhemoglobinemia occurred with high doses of this drug.  Methemoglobinemia may be related to NADH cytochrome b5 reductase deficiency or overdose, particularly in neonates.  Sulfhemoglobinemia usually occurred in adults with concomitant use of high doses of sulfur-releasing products.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Angioneurotic edema, maculopapular rash, rash, urticaria<sup>[Ref]</sup></p><p>Rash and urticaria typically occurred in patients with a history of asthma.<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Extraocular muscle spasm, oculogyric crisis, visual disturbances<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Fluid retention, porphyria<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories, Philadelphia, PA. </p><h2>More about Gimoti (metoclopramide)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: GI stimulants</li>
<li>FDA Alerts (3)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Gimoti &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Gastroparesis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>